Why the study?
Does recombinant human IL-37 reduce myocardial ischaemia/reperfusion injury in male C57BL/6J mice?
Does recombinant human IL-37 reduce myocardial ischaemia/reperfusion injury in male C57BL/6J mice?
IL-37 ameliorates myocardial ischaemia/reperfusion injury in mice by suppressing innate immunity and inflammation, highlighting its potential as a therapeutic agent.
No takes yet. Share an insight, caveat, or question.
IL-37 merits further study in myocardial I/R injury; hypothesis-generating in mice and should not change clinical practice.
Wu et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: